摘要
目的:探讨新辅助化疗对食管鳞状细胞癌组织中趋化因子受体-7(CCR7)和血管内皮生长因子-C(VEGF-C)表达的影响。方法:25例食管癌患者(新辅助化疗组)术前进行化疗2周期后手术;与新辅助化疗组初诊时期别相同的食管癌患者45例(单纯手术组)术前均未进行化疗和放疗。用免疫组织化学SP法测定手术切除标本中CCR7和VEGF-C的表达,并进行分析。结果:新辅助化疗组淋巴结转移率和CCR7、VEGF-C阳性率分别为24.0%(6/25)、48.0%(12/25)和20.0%(5/25),单纯手术组分别为55.6%(25/45)、75.6%(34/45)和68.9%(31/45),新辅助化疗组淋巴结转移率、CCR7和VEGF-C阳性率均低于单纯手术组(χ2分别为6.48,5.41,15.28,P均<0.05)。单纯手术组CCR7蛋白与VEGF-C蛋白表达呈正相关(rs=0.623,P<0.05)。结论:新辅助化疗可能通过下调组织中CCR7和VEGF-C的表达,从而减少食管鳞状细胞癌的淋巴结转移。
Aim：To explore the effect of neoadjuvant chemotherapy on the expressions of CCR7 and VEGF-C in esophageal squamous cell carcinoma（ESCC） tissue.Methods：The expressions of CCR7 and VEGF-C in 45 specimens of ESCC removed by operation only（operation only group） and 25 specimens removed by operation following the neoadjuvant chemotherapy（neoadjuvant chemotherapy group） using immunohistochemistry method.Results：The lymphatic metastasis rate,the rate of CCR7,VEGF-C positive expression in neoadjuvant chemotherapy group were 24.0% （6/25） ,48.0% （12/25）,20.0% （5/25） , respectively, much lower than those of operation group, which were 55.6% （ 25/45 ） ,75.6% （ 34/45 ） , 68.9 % （ 31/45 ） , respectively （χ^2 was 6.48,5.41,15.28, respectively, P 〈 0.05 ）. The expression of CCR7 in operation only group was positively correlated to that of VEGF-C （r = 0. 623 ,P 〈 0.05 ）. Conclusion ： Neoadjuvant chemotherapy may down-regulate the expressions of CCR7 and VEGF-C in ESCC tissue, which potentially tend to reduce lymphatic metastasis.
出处
《郑州大学学报（医学版）》
CAS
北大核心
2009年第4期705-707,共3页
Journal of Zhengzhou University(Medical Sciences)
